Is anyone closely tracking this counter? With expected weak Q3 behind us and revenue bookings of Revlimid expected in Q1 and Q2, current valuations look very attractive.
Any major overhang that anyone is aware of for it to trade at such tempting valuations?
| Subscribe To Our Free Newsletter |
